# Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND

> **NCT06954155** · PHASE3 · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 330 (estimated)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Tenecteplase (0.25mg/kg)
- **DRUG:** Standard medical treatment

## Key facts

- **NCT ID:** NCT06954155
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-05-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954155, "Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06954155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*